Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: HIV Infections, Hyperlipidemia
Interventions: Pravastatin, Darunavir, Ritonavir, Washout; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Familial Hyperlipidemia
Interventions: Not listed
Lead sponsor: Poudre Valley Health System; Other
Eligibility: 6 Years to 10 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loveland, Colorado

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 63
States / cities: Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more

Conditions: Primary Dyslipidemia, Mixed Dyslipidemia
Interventions: pitavastatin, pravastatin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 41 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Scottsdale, Arizona • Cincinnati, Ohio

Conditions: Hypertension, Hyperlipidemia
Interventions: HL040XC, Losartan + Atorvastatin; Drug
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 19 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more

Conditions: Hypertriglyceridemia
Interventions: POM3, Placebo; Drug
Lead sponsor: Provident Clinical Research; Other
Eligibility: 18 Years to 79 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Peripheral Arterial Disease
Interventions: Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.; Drug · Other
Lead sponsor: Leonardo Clavijo; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: ASCVD, Elevated Cholesterol
Interventions: Inclisiran Sodium, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 145
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more

Conditions: HIV Infections, Hypertriglyceridemia
Interventions: Fenofibrate, Fish Oil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Cincinnati, Ohio + 2 more

Conditions: Overweight, Elevated Cholesterol
Interventions: Lyzme5; Dietary Supplement
Lead sponsor: Jeff Golini; Industry
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Billings, Montana

Conditions: Hyperlipidemia
Interventions: Self Monitoring Lipid Analyzer; Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiovascular Diseases, Myocardial Infarction, Atrial Fibrillation, Diabetes Mellitus, Heart Failure, Hyperlipidemias, Hypertension, Ischemic Heart Disease, Stroke, Transient Ischemic Attack
Interventions: Care coordination delivered based on perceived need, Care coordination delivered based on usual care (e.g. discharge from hospital); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Familial Hypercholesterolemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Healthy Volunteers
Interventions: Placebo, PF-06427878; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Glendale, California • South Miami, Florida

Conditions: Diabetes Mellitus Type 2, Dyslipidemia, Hypercholesterolemia, Obesity
Interventions: removal of omentum; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis; Biological · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more

Conditions: Hypercholesterolemia
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Auburn, Maine

Conditions: Healthy
Interventions: RN316; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Phoenix, Arizona • Miami Gardens, Florida

Conditions: Stroke, TIA, Hypertension, Hyperlipidemia
Interventions: TI, AP; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Hypercholesterolemia, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolemia, Flushing
Interventions: Apple pectin, Aspirin 325 mg, Placebo; Other · Drug
Lead sponsor: Patrick Moriarty, MD, FACP, FACC; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hypercholesterolemia and Hyperlipidemia
Interventions: Ketogenic Diet, Control Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

School-based Education and Screening Program With Lipid Screening as a Means to Identify Familial Hyperlipidemia

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

Telephone Based Management of Hyperlipidemia

Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

Omentectomy for the Treatment of Diabetes Mellitus Type 2

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

Reducing Risk of Recurrence

The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients

Alternative Options to Minimize Niacin-Induced Flushing

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia